
Kennametal India reports ₹1.43B pretax profit as hard-metal sales climb
The hard-metal division nearly doubled revenue, while favourable timing between raw-material pricing and costs helped lift profitability.

The hard-metal division nearly doubled revenue, while favourable timing between raw-material pricing and costs helped lift profitability.

International medical sales supplied 59 per cent of quarterly revenue, while gross margin and adjusted EBITDA declined sequentially.

Operating cash flow reached US$9.5 million as expansion spending eased, but weaker Canadian wholesale pricing reduced cannabis profit.



A US$36M tariff benefit lifted gross margin, while net cash and investments slipped and fourth-quarter sales guidance came in lower.
Available liquidity stood near US$700M at Sept. 30 as the company advanced a US$2.3B Great Basin expansion targeting service in late 2028.
Third-quarter revenue reached US$393.1 million, while the medical-device maker kept its annual adjusted free-cash-flow target unchanged.
Cash and investments fell US$41.9 million over the quarter as the gene therapy developer prepared for a potential AMT-130 launch.
Cash reached US$48.2 million as licensing supported operations, while approaching hemp restrictions threaten current products.
Quarter-end liquidity excludes a US$250 million loan draw and a US$70 million payment due under its amended licensing deal.
Genomic analysis volume reached a record 118,000 as the company narrowed its adjusted EBITDA loss and targeted the upper end of annual guidance.
Electrical Americas backlog reached US$16 billion as new manufacturing capacity helped lift its margin from the preceding quarter.
Adjusted earnings guidance rises to US$2.95 to US$3.05 a share as non-COVID products grow and Pfizer appoints a permanent CFO.
The generator kept its cash-flow and adjusted EBITDA forecasts while raising 2026 sustaining capital spending to C$350M to C$370M.
The New Jersey utility and nuclear owner kept its 2026 earnings outlook and expects to fund a US$24B to US$28B capital plan without new equity.
Quarterly sales rose 39 per cent as Mounjaro and Zepbound demand outweighed price declines, while acquisition charges weighed on earnings.
The utility forecasts 2027 adjusted earnings of US$2.22 to US$2.30 a share, with data centre investments supporting faster growth.
Adjusted EPS guidance rises to US$18.30 to US$18.70 as stronger cash generation accompanies higher capital spending.
The utility retains its US$24 billion capital plan while separating operating demand from signed load additions in a 745 MW total.
Adjusted operating income turned positive, but an insurance benefit lifted cash generation and the IFRS net loss reached C$50.8 million.
The benefit expense ratio improved to 90.6 per cent, but non-operating gains helped lift earnings and the annual forecast.
Net cash-cost guidance stays unchanged as by-product credits cushion higher diesel costs, with growth-project commissioning due to finish in 2027.
The adjusted earnings midpoint rises six cents to US$11.10 a share as drug sales grow faster than medical technology revenue.
BP flags US$3B to US$4.5B in total post-tax impairments, primarily attributable to transition businesses, ahead of Oct. 30 results.
Gross margin widened to 30 per cent, but cannabis revenue declined; Tilray retained its fiscal 2027 adjusted EBITDA target.
Greenland completed its IPO in 2018 and merged with Hong Kong's Zhongchai Holding the following year
Revenue mushrooming was attributed to the company's cannabis operations and functional fungi drinks
22 stores have been on strike since May 20
Biosteel net revenue increased by 299% compared to the same quarter in the previous year
Operating expenses went down this quarter by 42.1 per cent to $73.9 million from $127.7 million in the third quarter
The company says its lower revenue was caused by lower bulk sales as well as the B.C. strike and OCS cyberattack
The company credits its recent financial success to the acquisitions of Alpha Growers and Magic 1 Promotions
The company reported an international cannabis revenue of $10.4 million
The company attributes its recent financial success to CBD and oil-absorbing product distribution
Net loss for Q4 was $618.8 million which was due to non-cash impairment charges of $505.1 million
Of the 28 stores represented by the Confédération des syndicats nationaux, 22 have been on strike since May 20
Khiron says it has developed a proven clinic business model with highly profitable medical cannabis sales in Colombia, the United Kingdom, Peru, Brazil and Germany.
The company said there was a significant downturn in the California and Oregon markets